

Supplementary Materials: Systematic Review of Advances in Targeted Therapy for Anaplastic Thyroid Cancer

Table S1. Reported follow-up, loss to follow-up, and treatment discontinuation in the included trials.

	Follow Up Reported	No. of Patients	Unavailable for Response Evaluation	No. of Treatment Discontinuations
Kloos [49]	No	56 (4 with ATC)	2 patients (3.4 %) - Unreported reasons	54 patients (93 %) - 35 due to progressive disease - 14 due to AEs - 1 due to other unreported reasons
Savvides [50]	No	20	2 patients (10 %) - Due to disease progression	NA
Ito [51]	No	18 (10 with ATC)	None	3 patients (17 %) - Due to AEs
Sherman [52]	No	36 (2 with ATC)	6 patients (17 %)	35 patients (97 %) - 12 due to withdrawal of consent - 10 due to progressive disease - 5 due to excessive toxicity
Bible [53]	No	16	1 patient (6.25 %) - Cancellation before treatment for unknown reasons	15 patients (100 %) - 12 due to progressive disease - 1 due to death - 2 due to AEs
Ha [54]	Yes	11	3 patients (27.3 %) - Lack of radiological evaluation	1 patient (9 %): - AE not related to the treatment or disease
Tahara [55]	No	60 (17 with ATC)	9 patients (15 %) - Did not meet inclusion criteria	13 out of 17 ATC patients (77 %) - 12 due to progressive disease - 1 due to suicide attempt
Ravaud [56]	Yes	71 (4 with ATC)	6 patients (8 %) (two with ATC)	62 patients (87 %) - 38 due to death - 18 due to loss to follow-up
Hyman [57]	No*	122 (7 with ATC)	2 patients (2 %) - Withdrew early, reason not reported	At least 4 due to AE** (3 %)
Subbiah [58]	Yes	16	None	3 patients (19 %)

				- 2 due to AE - 1 due to PD
Lim [59]	Yes	40 (6 with ATC)	5 patients (12.5 %) - 2 withdrew consent before treatment for unknown reasons - Outcomes of 3 patients are missing for unknown reasons	23 patients (58 %) - 2 withdrew consent before and 3 during treatment for unknown reasons - 1 due to AE - 14 due to disease progression
Schneider [60]	Yes	35	None	1 patient (3 %) - Due to AE
Hanna [34]	Yes	50 (7 with ATC)	6 patients (12 %) (1 with ATC)	46 patients (92 %) - Progressive disease
Pennel [61]	Yes	27 (5 with ATC)	2 patients (7.4 %) - Both due to AE	2 patients (7.4 %) - The same two unavailable for evaluation
Cohen [62]	Yes	60 (2 with ATC)	15 patients (25 %) - 8 did not meet response criteria - 7 missing post baseline data for unknown reasons	60 patients (100 %) For both studies: - 20 had insufficient clinical response - 14 planned to enroll in the ongoing extension study - 11 due to non-fatal AEs - 4 due to fatal AEs - 9 refused further participation - 2 lost to follow-up
Mooney [63]	Yes	26	None	1 patient (4 %)
Sosa [64]	No	80	5 patients (6.25 %) - 2 due to patient refusal - 1 did not meet inclusion criteria - 1 due to investigators' decision	50 patients (67 %) - 40 due to disease progression - 6 withdrew or refused - 2 due to AE - 1 unreported reason

* Study still ongoing. ** Only reported for the cohort with Erdheim–Chester disease or Langerhans' cell histiocytosis.